Evidence-grounded market and regulatory briefs built for fast scanning, comparison, and strategic follow-up.
FDA approvals now establish a US lipid nanoparticle precedent across siRNA therapeutics and mRNA vaccines. The regulatory record highlights recurring CMC issues in release testing, comparability, stability, specialized lipid control, and lifecycle manufacturing.
A research brief on therapeutic aging science, with emphasis on OSK partial reprogramming, first-in-human development, and the broader translational gap between longevity biology and approvable medical products.
How adalimumab, infliximab, etanercept, certolizumab pegol, and golimumab now differ on biosimilar depth, route strategy, regional status, and commercial posture.
IL-6 in 2026 is no longer a single-brand category. The market is defined by a crowded tocilizumab franchise, narrower approved positions for sarilumab, satralizumab, and siltuximab, and a late-stage pipeline that is pushing the pathway into new neurologic and cardiometabolic settings.
Selective IL-23-pathway therapies now span skin, joints, bowel disease, biosimilar-exposed legacy products, and the first oral IL-23 receptor antagonist, creating a more segmented and strategically important market than the earlier psoriasis-only class.
How the IL-17 class now divides between mature IL-17A incumbents, a fast-scaling IL-17A/F challenger, and a narrower next wave of pipeline assets.